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ABSTRACT 
 
Aims: To present 12 new variants of uracil mustard having drug-like properties and cytotoxic 
functional group, by utilizing uracil mustard (uramustine) as a lead compound. Utilize rigorous 
substructure and similarity of a molecular scaffold to determine drug like variants. Physicochemical 
properties determined indicate the variants have favorable drug-likeness.  
Study Design: Conduct molecular database search utilizing features of substructure and similarity 
based upon uracil mustard. 
Place and Duration of Study: Department of Chemistry, Medicinal Chemistry Study Section, 
University of Nebraska at Omaha, Omaha Nebraska between January 2015 to March 2015.  
Methodology: Uracil mustard consists of the pyrimidine derivative uracil, having the bifunctional 
nitrogen mustard cytotoxic moiety covalently bonded onto the ring. A systematic search, utilizing 
substructure component and similarity, within an in-silico database search successfully determined 
12 variants. Rigorous criteria for drug-likeness was implemented to screen potential candidates 
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that included the application of the Rule of 5. In addition, maintaining the cytotoxic moiety of 
nitrogen mustard was crucial. 
Results: A total of 12 variants of uracil mustard was identified after an extensive molecular 
database search using rigorous criteria.  All 12 variants, and including uracil mustard, showed zero 
violations of the Rule of 5, thereby indicating favorable drug-likeness. Values of polar surface area 
for all compounds at less than 80 Angstroms
2
 are suitable for central nervous system penetration. 
Polar surface area, number of atoms, and Log P for all compounds increased as the molecular 
weight increases. Structure substituents include nitrogen mustard groups, hydroxyl, alkyl and 
carbonyl moieties. Cluster analysis discerned greatest similarity among members of this group.  
Conclusion: Applying rigorous search criteria within a molecular data base, for comparison and 
reject, successfully identified 12 variants of uracil mustard that show favorable drug-likeness in 
addition to cytotoxic capability. The design of new antitumor agents is important for increasing 
efficacy of the clinical treatment of cancer. 
 
 
Keywords: Uracil mustard; uramustine; cancer; leukemia; lymphoma. 
 
ABBREVIATIONS 
 
Term: PSA, polar surface area; A, angstroms; MW, molecular weight; n Atoms, number of atoms; 
nOHNH, number hydroxyl and amine groups; nON, number of oxygen and nitrogen atoms. 
 
1. INTRODUCTION  
 
Uramustine or uracil mustard is an alkylating 
chemotherapy agent that is particularly effective 
for the treatment of lymphomas, Non-Hodgkin’s 
lymphoma, chronic lymphocytic leukemia, 
chronic myelogenous leukemia and chronic 
leukemias [1,2]. It is used in lymphatic 
malignancies such as non-Hodgkin's lymphoma. 
Nitrogen mustard agents alkylate the DNA and 
thereby induce damage to the DNA, which in turn 
is a cytotoxic effect primarily to cancer cells [1].  
This due to the take up of uracil due to the need 
to form nucleic acids during rapid cycles of cell 
division. The DNA damage (cross-linking) leads 
to apoptosis of the affected cells. This agent is 
cell cycle-phase nonspecific. Chemically it is a 
derivative of nitrogen mustard and uracil. Notable 
among its advantages are: 1) Small dose 
requirement; 2) Uniform tolerability; 3) Simple 
regimen requirements [1]. 
 
Previous studies have shown the efficacy of 
uracil mustard for the treatment of 
thrombocythemia, chronic lymphatic leukemia, 
and lymphoma [3]. Investigators record objective 
improvement in patients having solid tumor, 
lymphoma, and leukemia [4,5]. Clinical studies 
have also demonstrated the effectiveness of 
uracil mustard for treatment of Hodgkin disease, 
non-Hodgkin lymphoma, and chronic lymphatic 
leukemia [6- 9].  
 
Uracil mustard has been shown to bring about a 
dramatic relief in patients having Hodgkin’s 
disease and multiple myeloma, in addition to be 
well tolerated [10]. After extensive clinical trials 
this agent has been found effective in treatment 
of granulocytic leukemias [10] and childhood 
acute leukemia [11]. Uracil mustard is declared 
an effective drug for controlling thrombocytosis 
with minimal effects on leukocytes and 
erythrocytes [12]. In the case of elderly patients 
fighting non-Hodgkin’s lymphoma, the fifth most 
common malignancy for male and female in the 
United States, the use of uracil mustard would be 
effective [13,6,7]. This lymphoma originates in 
the lymphatic system, causing greater than 
18,000 deaths in the United States annually. 
Uracil mustard and 5-fluorouracil in combination, 
have been shown to be an extremely effective 
chemotherapy [14]. 
 
In-silico studies have been successful for 
characterizing the molecular activity of uracil 
mustard with cellular targets such as DNA [15]. 
Optimization of molecular scaffolding with 
concurrent elucidation of physicochemical 
properties has been successful for 
characterization of drug efficacy treating dermal 
neoplasm [16]. This study presents 12 variants of 
uracil mustard resulting from in-silico 
substructure and similarity mining with use of 
rigor enjoined by uracil mustard scaffolding 
parametric limitation. 
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2. MATERIALS AND METHODS  
 
2.1 Molecular Modeling and Assembly of 
Molecular Variants  
 
Molecular modeling (2-D) was accomplished 
utilizing ACD/Chem Sketch modeling v. 10.00 
(Advanced Chemistry Development, 110 Yonge 
Street, Toronto Ontario, M5C 1T4 Canada). In 
silico structure search for a substituent 
replacement was accomplished using chemical 
substructure and similarity search with Molsoft 
L.L.C. (Molsoft L.L.C. 11199 Sorrento Valley 
Road, S209 San Diego, CA 92121) and 
Molinspiration (Molinspiration Chemiformatics, 
Nova ulica 61, SK-900 26 Slovensky Grob, 
Slovak Republic). Various properties such as 
polar surface area, violations of Rule of 5, 
molecular volume, number of oxygens, nitrogens, 
amines (-NHn) and hydroxyls (-OH), were 
determined using Molinspiration Properties 
Calculations module (Molinspiration 
Chemiformatics, Nova ulica 61, SK-900 26 
Slovensky Grob, Slovak Republic). Biological 
activity of all compounds was determined by 
Molinspiration drug-likeness and bioactivity 
scoring (Molinspiration Chemiformatics, Nova 
ulica 61, SK-900 26 Slovensky Grob, Slovak 
Republic). 
 
2.2 Pattern Recognition  
 
To identify underlying associations and patterns 
within the descriptors multivariate numerical data 
matrix, then various pattern recognition 
techniques were implemented. Included in this 
analytical approach is a hierarchical cluster 
analysis accomplished by KyPlot v. 2.0 Beta 15 
(copyright Koichi Yoshioka 1997-2001). Other 
pattern recognition elucidation by K-means 
nonhierarchical cluster analysis and discriminant 
analysis were performed by PAST v. 1.80 
(copyright Oyvind Hammer, D.A.T. Harper 1999-
2008).   
 
2.3 Numerical Analysis of Multivariate 
Physicochemical Properties  
 
Descriptive statistical analysis, Pearson r, and 
coefficient of determination for all numerical data 
where indicated was performed by Windows 7 
Microsoft Office Professional Plus 2013 EXCEL 
(EXCEL 2013).  Screening for numerical outliers 
was done by Grubb’s Test (extreme studentized 
deviate) by GraphPad Software (2236 Avenida 
de la Playa, La Jolla, CA 92037 USA). Multiple 
regression analysis was performed by GraphPad 
InStat v. 3.0 for Windows 95 (HJ Motulsky, 
GraphPad InStat 3.0 GraphPad Software, Inc., 
San Diego California USA, www.graphpad.com). 
 
3. RESULTS AND DISCUSSION 
 
Uracil mustard (uramustine) is known to be 
effective in the treatment of a multitude of 
neoplastic diseases. Data mining for substructure 
replacement has undergone progress in recent 
years and presents an efficacious tool for drug 
design, particularly with the presence of effective 
parent constructs that are applied in seeding the 
mining process [15,16]. Utilizing uracil mustard 
as the parent compound for drug design (see 
compound 1, Fig. 1) the outcome nitrogen 
mustard agents 2 through 13 were determined 
after an algorithmic search process generating 
numerous candidates, of which, included those 
having unfavorable bioavailability attributes (ie. 
high formula weight and polar surface area) to be 
identified and eliminated. This rate of ruination 
makes it necessary of having information 
descriptive of successful candidates, concerning 
the desired (drug-like) physicochemical 
properties. Therefore, substituent replacement is 
clearly an important approach in rational drug 
design [17]. 
 
In general, the aromatic heterocyclic organic 
pyrimidine ring remains in addition to the 
bifunctional cytotoxic nitrogen mustard group that 
renders the alkylating antineoplastic action. The 
parent compound with 12 variants are presented 
in Fig. 1. The variants of uracil mustard are 
essentially derivatives having an additional 
substitution in place of the hydrogen (-H) located 
onto N-3. Substituents located onto N-3 then will 
introduce variations of pharmaceutical properties 
such as Log P, polar surface area, molecular 
weight, etc. It is vital to maintain a favorable 
drug-likeness of properties while inducing 
variation that would benefit the clinical efficacy of 
the compound. The drug-likeness of the 
compounds was monitored and rigorously made 
to adhere to the Rule of 5, which is a robust 
approach to identify potential drugs having good 
membrane permeability and orally active (easily 
absorbed) [18]. An orally active drug will have no 
more than one violation of the following      
criteria [18]: 1) No more than 5 hydrogen bond 
donors (-OH and -NHn); 2) Not more than 10 
hydrogen bond acceptors (all nitrogen or oxygen 
atoms); 3) A molecular mass less than 500 
Daltons; 4) An octanol-water partition coefficient 
Log P not greater than 5. 
 
The molecular structure of uracil mustard, with 
12 variants are presented in Fig. 1. Notably, each 
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structure possesses the nitrogen mustard group 
responsible for the nucleic acid alkylating 
cytotoxic activity (located at the C-5 position). All 
variations of uracil mustard (#2 to #13) have 
substituents on the N-3 position. Beginning with 
compound #2, the N-3 substituent is an acyl 
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Fig. 1. Molecular structure of uracil mustard and its variants. The molecular scaffolding 
includes the pyrimidine derivative uracil, alkylating nitrogen mustard moiety (covalently 
bonded to C-5), hydroxyl, alkyl, and carbonyl moieties (collectively attached to the pyrimidine 
uracil on N-3) 
 
group: (CH3C(=O)-), followed by compound #3 
having a propanoyl group (CH
followed by compounds #4 to #8 having alkyl 
substitutions:(CH3(CH2)nC(=O)-) where n = 2 to 
6, respectively. Compounds #2 to #8 constitute a 
homologous series that differ by a constant unit
or generally a (-CH2-) group. These
have been shown to have similar and often times 
increasing beneficial medicinal activity [19].
Likewise, for compounds #11 to #13 shown in 
Fig. 1, the N-3 position has substituents 
(-C(OH)(CH2)nCH3) where n = 3 to 5, 
respectively. Hence, two homologous series of 
compounds have been identified within this 
group of compounds. 
 
Physicochemical properties useful for evaluating 
pharmaceutical potential are presented for all 13 
compounds, see Table 1. Noteworthy points 
include the very strong positive correlation 
(Pearson r > 0.9000) for Log P to the number of 
atoms, molecular weight, rotatable
molecular volume. In addition, there is a strong 
positive correlation (Pearson r > 0.6000) for polar 
surface area to the number of atoms, molecular 
weight and molecular volume. The range in Log 
P values for this group of compounds is broad 
(0.563 to 3.968), having value of 3.405.
studies have shown the efficacy of varying the 
Log P of medicaments in the case of 
antineoplastic drugs [16], as well as antibacterial 
drugs [20-22]. In these studies the medicinal 
activity of the agent was increased in the case of 
antibacterial drugs or enhanced for antineoplastic 
agents. 
 
Notably, all compounds have zero violations of 
the Rule of 5, indicating favorable membrane 
permeation and absorption (i.e. drug
Values of polar surface area are kept 
a small range of 68.9 Angstroms
Angstroms
2
. These values again indicate 
favorable drug absorption [23]. 
investigation as to drug-likeness of known 
pharmaceuticals suggest that all compounds #1 
to #13 would be greater than 50% absorbed 
the intestinal tract [23]. These properties support 
the potential of the 12 variants of uracil mustard.
 
Further understanding of the underlying 
relationships between these compounds is 
accomplished using pattern recognition method 
of hierarchical cluster analysis (a multilevel 
hierarchy, where clusters at one level are joined 
as clusters at the next level) [24].
hierarchical cluster analysis utilizing a single 
linkage (minimum distance between elements of 
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low, having 
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 to 78.3 
Previous 
from 
 
 Results of 
each cluster) and utilizing Euclidian distance (the 
most common distance measure, are the 
geometric distance in multidimensional space) is 
presented in a divisive vertical dendrogram (see 
Fig. 2). 
 
Interestingly, the compounds #2 to #8 are 
clustered together to be more simil
other and joined at node C. It follows, that 
compounds #9 to #13 are likewise determined to 
be more similar to each other and joined at node 
D. These two clusters are in turn joined at super 
node B. The super node A joins node B to the 
parent compound (#1). This analysis has 
distinguished the parent compound uracil 
mustard (#1) from the 12 variations of ring 
substituents.  
 
 
Fig. 2. Hierarchical cluster analysis utilizing 
single linkage with Euclidean distance. 
Compound 1 is uracil mustard joined at node 
A with all remaining compounds. Node B 
joins compounds 2 to 13 into two sub 
clusters under node C (2, 3, 4, 5, 6, 7 and 8) 
and node D (9, 10, 11, 12, and 13)
 
Other trends in properties can be discerned by 
non-hierarchical cluster analysis. K
cluster analysis is used to classify observations 
through a K number of clusters, and aims to find 
a grouping of objects which maximizes or 
minimizes some evaluating criterion [24]. Results 
of K-means cluster analysis places these 
compounds into four distinct clusters, as follows: 
Cluster 1) compounds #4, #5, #9, #10; cluster 2) 
compounds #6, #7, #11, #12; cluster 3) 
compounds #8, #13; cluster 4) uracil mustard 
(#1), compounds #2, and #3. Therefore, a 
connectivity is identified among the pa
compound uracil mustard and variants #2 and
#3. To follow, the analogy is determined by 
discriminant analysis being a process used 
todetermine which variables discriminate
between two or more naturally occurring groups. 
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Table 1. Physicochemical properties of compounds 
 
Drug Log P Polar 
surface 
area (A
2
) 
Number 
of 
atoms 
Molecular 
weight 
Number 
O & N 
Number 
of –OH 
& -NH2 
Rule 
of 5 
violations 
Rotatable 
bonds 
Molecular 
volume 
(A
3
) 
1 
uramustine 
0.563 68.9 15 252.1 5 2 0 5 199.0 
2 0.885 75.2 18 294.1 6 1 0 5 234.9 
3 1.387 75.2 19 308.2 6 1 0 6 251.8 
4 1.947 75.2 20 322.2 6 1 0 7 268.6 
5 2.452 75.2 21 336.2 6 1 0 8 285.4 
6 2.957 75.2 22 350.3 6 1 0 9 302.2 
7 3.462 75.2 23 364.3 6 1 0 10 319.0 
8 3.968 75.2 24 378.3 6 1 0 11 335.8 
9 1.298 78.3 20 324.2 6 2 0 7 273.9 
10 1.858 78.3 21 338.2 6 2 0 8 290.7 
11 2.363 78.3 22 352.3 6 2 0 9 307.5 
12 2.868 78.3 23 366.3 6 2 0 10 324.3 
13 3.373 78.3 24 380.3 6 2 0 11 341.1 
A2 =Angstroms2; A3 =Angstroms3 
 
Results of discriminant analysis indicate the 
commonality among uracil mustard (#1) to 
compounds #9, #10, #11, #12, and #13 
(compounds having alcoholic homologous 
series). Distinct from these compounds are those 
compounds #2, #3, #4, #5, #6, #7, and #8 
(compounds having alkanoyl homologous 
series).  
 
Grubbs' test, also known as the maximum 
normed residual test or extreme studentized 
deviate test, is a statistical test used to detect 
outliers in a univariate data set assumed to come 
from a normally distributed population [25]. 
Analysis of all 13 compounds for outliers utilizing 
Grubb’s test, showed no outliers among the 
values of Log P, the number of atoms, molecular 
weight, number of oxygen/nitrogen atoms, and 
molecular volume. These findings, shows 
consistency with the parent drug uracil mustard. 
 
Other discernable and highly linear trends of 
these compounds are the steadily increasing 
polar surface area (Pearson r = 0.6887) and 
number of atoms (Pearson r = 0.9996) as 
dependent variables, when compared to 
molecular weight (independent variable), see   
Fig. 3.  
 
A 2-way plot of Log P (dependent variable) to 
molecular weight (independent variable) 
indicated an increasing strong exponential trend 
(R
2
 = 0.9307), see Fig. 4. The increase of Log P 
within a homologous series of compounds has 
been determined in previous studies to generally 
enhance and improve medicinal activity [19]. The 
rise in Log P values corresponding increase of 
molecular weight is consistent with homologous 
series of drug agents and found in other studies 
[20-22]. 
 
The general goal of multiple regression is to 
learn more about the relationship between 
several independent or predictor variables and a 
dependent or criterion variable. One use of 
multiple regression is a prediction or estimation 
of an unknown, dependent Y value 
corresponding to a set of independent X values. 
A second application of multiple regression is to 
understand the functional relationships between 
the dependent and independent variables, to try 
to see what might be causing the variation in the 
dependent variable [24]. Multiple regression 
analysis of the descriptors presented in Table 1 
resulted in a mathematical description that 
accounts for 100% of the variance within the 
model (R2 = 1.000). The properties applied 
include molecular weight (MW), polar surface 
area (PSA), number of atoms (nAtoms), number 
of hydroxyl and amine groups (nOHNH), number 
of oxygen & nitrogen atoms (nON) and molecular 
volume (MV). The model is expressed as follows: 
 
MW = 36.521 + 0.74068(PSA) +5.900(nAtoms) 
- 2.155(nOHNH) -1.036(nON) + 0.5455(MV) 
 
The equation describing the model can be used 
to predict important molecular properties that will 
allow the additional design of analogous 
compounds. 
 
The diversity of potential drug targets is so 
enormous, that it is possible to find a common 
denominator for all of them [26]. The strategy 
which leads to success is focus on particular 
drug classes and the development of the specific 
activity score for each of these classes. This is 
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accomplished for compounds presented in this 
study and listed in Table 2. The distribution of 
activity scores for the four most important drug 
classes is presented in Table 2. For ion channel 
modulator activity and drug-likeness, the best 
score falls between -1.30 to 0.50 [26]. For kinase 
inhibitor activity and drug-likeness, the best score 
falls between -1.30 to 0.50 [26]. For protease 
inhibitor activity and drug-likeness, the best score 
falls between -1.10 to 0.50 [26]. For other 
enzyme inhibitor activity and drug-likeness, the 
best score falls between -1.10 to 0.50 [26]. 
Therefore, all compounds (#1 to #13) presented 
in this study show the best biological activity 
score for active compounds and drug-likeness. 
This is further evidence that these variants of 
uracil mustard will be effective and useful in 
clinical application. 
  
 
Fig. 3. Comparison of polar surface area and number of atoms (dependent variables) to 
compound molecular weight (independent variable). Number of atoms are highly linear with 
very strong positive relationship (Pearson r = 0.9996, coefficient of determination, R
2
 = 0.9993) 
with increase of molecular weight. Polar surface area is highly linear to increase of molecular 
weight with a strong positive relationship (Pearson r = 0.6887, coefficient of determination  
R
2
 = 0.4743) 
 
 
 
Fig. 4. Trend for Log P compared to molecular weight increase is a steady increase along 
(coefficient of determination, R
2
 = 0.9307, correlation coefficient r = 0.9647) 
R² = 0.9307
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Table 2. Biological activity of compounds by score 
 
Drug  Ion channel 
modulator  
Kinase 
inhibitor 
Protease 
inhibitor 
Enzyme  
inhibitor 
1 uramustine -0.76 -0.50 -1.03 -0.26 
2 -1.02 -0.05 -0.52 -0.14 
3 -0.92 -0.08 -0.48 -0.11 
4 -0.88 0.04 -0.40 0.0 
5 -0.83 0.08 -0.32 0.02 
6 -0.79 0.10 -0.27 0.02 
7 -0.76 0.11 -0.23 0.01 
8 -0.73 0.11 -0.20 0.01 
9 -0.39 0.33 -0.15 0.16 
10 -0.37 0.34 -0.09 0.17 
11 -0.35 0.35 -0.03 0.18 
12 -0.33 0.35 0.0 0.17 
13 -0.32 0.34 0.02 0.17 
 
The design of anticancer drugs is an important 
aspect for the clinical treatment of cancer. 
Improvement in the treatment and improvement 
of clinical outcome is enhanced by the 
introduction of the versatile and novel drugs 
initiated by rational drug design. Presented here 
are 12 variations of uracil mustard that have 
shown useful drug-likeness and possess the 
cytotoxic nitrogen mustard alkylating functional 
group. Further studies of novel drug designs 
would be useful for advancing the treatment of 
cancer. 
 
4. CONCLUSION 
 
Twelve structures which are variants of uracil 
mustard were identified utilizing rigorous 
physicochemical criteria of substructure and 
similarity to this nitrogen mustard anticancer 
agent. Additions to the scaffold of uracil mustard 
included hydroxyl groups, alkyl carbon chains, 
and carbonyl groups. The wide range of Log P 
values from 0.885 to 3.968 contributes to a 
diverse potential in the use of these cytotoxic 
variants of uracil mustard, as shown in previous 
studies. Hierarchical cluster analysis and 
discriminant analysis distinguished uracil 
mustard from these variants, however K-means 
cluster analysis identified two variants having an 
acyl (CH3C(=O)-) group (#2) and propanoyl 
(CH3CH2C(=O)-) group (#3) bonded to the #3 
nitrogen of uracil base to be most similar to uracil 
mustard. As compound molecular weight 
increases the polar surface area, number of 
atoms and Log P increase, respectively. Multiple 
regression determined the equation accounting 
for 100% of variance modeling. Producing 
cytotoxic variants of uracil mustard showing zero 
violations of the Rule of 5 (good oral availability), 
this study demonstrates the efficacy of drug 
design following rigorous criteria for substructure 
and similarity. Design of novel or improved 
anticancer agents ultimately will benefit the 
patient as well as the clinical choices for 
treatment of neoplastic disease. Variation of 
physicochemical properties can benefit the 
efficacy of anticancer drugs and should be 
further investigated for the benefit of patients. 
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